International Journal of Health and Clinical Research

Yazarlar: Ishi Sharma, Rakesh Pandit, Prabhat Sinha, Vikramjeet Singh, Parinita Kaur, Harpreet Kaur

Konular:-

Anahtar Kelimeler:COVID,9,Corona Virus,Inflammatory Markers ,C,Eactive Protein,D,Imer,Procalcitonin.

Özet: Background: COVID-19 infections are increasing worldwide and treating these patients has become a major challenge for the clinicians. Inflammatory markers are very helpful in this scenario to partially classify patients into mild, moderate and severe disease and also to prioritize their clinical needs. This study is aimed to investigate serum levels of interleukin 6 (IL-6), C-reactive protein (CRP), lactate dehydrogenase (LDH), D-dimer and procalcitonin in COVID-19 patients, and to find the correlation of these parameters with disease severity and progression. Materials and Methods: This was a one year prospective study done between January 2020 and December 2020 and the sample size was 4308 COVID-19 infection positive cases. Inflammatory markers such as Lactate Dehydrogenase(LDH), C-reactive protein (CRP),D-Dimer, Procacitonin and Interleukin-6 were used to correlate with the disease severity of COVID -19 patients.Results: All the inflammatory markers were elevated in most of the COVID-19 patients and maximum elevation of these markers was seen in patients with co-morbid conditions. Patients with higher levels of these inflammatory markers required oxygen , ICU admissions and non-invasive or invasive ventilation. Conclusion: Inflammatory markers are very useful biomarkers which help clinicians in identifying severe disease earlier and subsequently improve prognosis.

---